However, this was predominantly driven by one trial, DECLARE TIMI 58, which included healthier cohorts than other cardiovascular outcome trials (CVOT) involving SGLT-2 inhibitors [103], and this benefit of asthma risk reduction was neutralized when DECLARE TIMI 58 was excluded from the analysis [105]
Early-stage clinical trials have produced unprecedented weight-loss results, eclipsing even the massive success of semaglutide ( Ozempic) and tirzepatide ( Mounjaro ), writes Hasina Kathrada for Mail & Guardian
Listen to your fullness signalsif you feel satisfied after one slice, you likely do not need more
Prebiotics promote good health: the basis, the potential, and the emerging evidence
Ive Heard About Some Pretty Yucky Side Effects With This Drug